| Literature DB >> 24176282 |
Adelina Ovcharenko1, Galit Granot, Oshrat Hershkovitz Rokah, Jennifer Park, Ofer Shpilberg, Pia Raanani.
Abstract
Concern about extramedullary relapse (EMR) despite favorable response in the bone marrow has been raised with the use of imatinib for treatment of chronic myeloid leukemia (CML). In the present study we show an increase in adhesion, migration and invasion capabilities of the CML cell line K562 following imatinib administration. Imatinib induced upregulation of Pyk2 mRNA and protein levels. Pyk2 inhibition resulted in a reduction of K562 cells' adhesion and migration subsequent to imatinib treatment. This effect was similar to that shown by us previously with all trans retinoic acid (ATRA) in the acute promyelocytic leukemia (APL) cell line NB4. Our data pinpoint Pyk2 as a shared key mediator of targeted-therapy induced adhesion and migration and may implicate that targeting Pyk2 may serve as an effective therapeutic strategy to reduce EMR in APL and CML.Entities:
Keywords: Adhesion; Chronic myeloid leukemia; Extramedullary disease; Imatinib; Migration; Pyk2
Mesh：
Substances：
Year: 2013 PMID： 24176282 DOI： 10.1016/j.leukres.2013.10.005
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156